NYSE:AIM

Aim Immunotech Stock Insider Trading

Healthcare > Biotechnology

Buy AIM

*Your capital is at risk

$0.732

-0.0947 (-11.46%)

At Close: Jun 03, 2026

AIM ImmunoTech Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 99.43. In total, the insiders bought 10.35M and sold 9.21K AIM shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	99.43
● Buy	10.35M shares
● Sell	9.21K shares
96% Buy Activity Negligible or No Correlation
Buy Signal High Confidence May 18, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 99.43. Confidence increased due to high data reliability score of 90. Supported by overwhelming buy-side pressure (96% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Dec 19, 2024 Buy	Common Stock	Kellner Ted D Director	Director	0 Value: $0
Dec 19, 2024 Buy	Common Stock	Kellner Ted D Director	Director	0 Value: $0
Dec 19, 2024 Buy	Common Stock	Kellner Ted D Director	Director	0 Value: $0
Dec 19, 2024 Buy	Common Stock	Kellner Ted D Director	Director	0 Value: $0
Dec 19, 2024 Buy	Common Stock	Kellner Ted D Director	Director	0 Value: $0
Dec 19, 2024 Buy	Common Stock	Kellner Ted D Director	Director	0 Value: $0
Dec 19, 2024 Sell	Common Stock S-Sale	Mitchell William M Director	Director	4 580 Value: $884
Dec 19, 2024 Sell	Common Stock S-Sale	Mitchell William M Director	Director	4 580 Value: $884
Dec 18, 2024 Buy	Common Stock P-Purchase	Equels Thomas K CEO & President	CEO / President	22 727 Value: $5K
Dec 18, 2024 Buy	Common Stock P-Purchase	Equels Thomas K CEO & President	CEO / President	22 727 Value: $5K
Dec 13, 2024 Buy	Common Stock A-Award	Mitchell William M Director	Director	24 452 Value: $5K
Dec 13, 2024 Buy	Common Stock A-Award	Appelrouth Stewart Director	Director	24 452 Value: $5K
Dec 13, 2024 Buy	Common Stock A-Award	Bryan Nancy Director	Director	24 452 Value: $5K
Dec 13, 2024 Buy	Common Stock A-Award	Bryan Nancy Director	Director	24 452 Value: $5K
Dec 13, 2024 Buy	Common Stock A-Award	Appelrouth Stewart Director	Director	24 452 Value: $5K
Dec 13, 2024 Buy	Common Stock A-Award	Mitchell William M Director	Director	24 452 Value: $5K
Dec 02, 2024 Buy	Common Stock P-Purchase	Appelrouth Stewart Director	Director	11 111 Value: $2K
Dec 02, 2024 Buy	Common Stock P-Purchase	Appelrouth Stewart Director	Director	1 Value: $0
Dec 02, 2024 Buy	Common Stock P-Purchase	Appelrouth Stewart Director	Director	1 Value: $0
Dec 02, 2024 Buy	Common Stock P-Purchase	Appelrouth Stewart Director	Director	11 111 Value: $2K
Dec 02, 2024 Buy	Common Stock A-Award	Mitchell William M Director	Director	22 645 Value: $5K
Dec 02, 2024 Buy	Common Stock A-Award	Bryan Nancy Director	Director	22 645 Value: $5K
Dec 02, 2024 Buy	Common Stock A-Award	Appelrouth Stewart Director	Director	22 645 Value: $5K
Nov 21, 2024 Buy	Common Stock P-Purchase	Equels Thomas K CEO & President	CEO / President	20 000 Value: $4K
Nov 21, 2024 Buy	Common Stock P-Purchase	Equels Thomas K CEO & President	CEO / President	20 000 Value: $4K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT AIM IMMUNOTECH INC.

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, n...

Read Full Profile Here